Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Phase 2, 6-month Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Phase 2, 6-month Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zervimesine (Primary)
  • Indications Dementia; Lewy body disease
  • Focus Adverse reactions; Proof of concept
  • Acronyms SHIMMER; SHIMMER DLB
  • Sponsors Cognition Therapeutics

Most Recent Events

  • 29 Jul 2025 According to a Cognition Therapeutics media release, results from this Phase 2 COG1201 SHIMMER study (NCT05225415) of zervimesine (CT1812) in dementia with Lewy bodies (DLB) at the Alzheimers Association International Conference (AAIC 2025).
  • 16 Jul 2025 According to a Cognition Therapeutics media release, data from this trial will be presented at the Alzheimer's Association International Conference (AAIC).
  • 25 Jun 2025 According to a Cognition Therapeutics media release, Based on the positive results from this study company have submitted application to be considered for breakthrough therapy designation.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top